A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world ...
aDepartment of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, 6825 N W 16th Street, Bld 54, Rm M003B, Washington, DC 20306-6000, USA, bDepartment of Thoracic Radiology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback